Monday, September 19, 2016
Ligand, TeneBio in Licensing Deal
San Diego-based Ligand Pharmaceuticals announced on Friday that it has entered into a worldwide license agreement with TeneoBio, covering the use of its OmniFlic antibody technology to discover fully human bispecific antibodies to be developed for the treatment of various diseases. The company said the initial focus will be on cancer, autoimmunity, and infectious diseases. Financial terms of the licensing deal wer enot announced. Ligand said the deal will provide it with platform access payments, sublicensing fees, milestone payments and royalties.